Prognostic factors for limited-stage small cell lung cancer: A study of 284 patients
Jun Chen(Dalian Medical University), Ping Yang(Milken Institute), Zhifu Sun(Mayo Clinic), Shawn M. Stoddard(Mayo Clinic), Ruoxiang Jiang(University of Minnesota Rochester), Yolanda I. Garces(Mayo Clinic), Aminah Jatoi(Mayo Clinic in Arizona), Yunpeng Liu(Shenyang Institute of Automation), Randolph S. Marks(Mayo Clinic)
Cited by 98
Related Papers
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508